The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFα PEGylated Fab′ monoclonal antibody

Toxicological Sciences

Volumn 122, Issue 1, 2011, Pages 170-176

  Wakefield, Ian ^a   Stephens, Sue ^a   Foulkes, Roly ^a   Nesbitt, Andrew ^a   Bourne, Tim ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Anti TNF monoclonal antibody; Homologues; Placental transfer; Rat; Reproductive toxicology; Surrogates

Indexed keywords

CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG CROSS REACTIVITY; DRUG MILK LEVEL; DRUG PROTEIN BINDING; DRUG SAFETY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; FEMALE FERTILITY; FETUS; FETUS DEVELOPMENT; MALE; MOLECULAR RECOGNITION; NONHUMAN; PLACENTAL TRANSFER; POSTNATAL DEVELOPMENT; PRENATAL DRUG EXPOSURE; RAT; REPRODUCTIVE TOXICITY; SPECIES DIFFERENCE;

PRIMATES; RATTUS;

EID: 79961011746     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr083     Document Type: Article

References (12)

1. Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F., Borenstein, D., Box, J., Coteur, G., Goel, N., Brezinschek, H. P., Innes, A., and Strand, V. (2009). Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous diseasemodifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68, 805-811.
2. Keystone, E., Heijde, D., Mason, D., Jr., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008). Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fiftytwo-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum. 58, 3319-3329.
3. Malek, A., Sager, R., Kuhn, P., Nicolaides, K. H., and Schneider, H. (1996). Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 36, 248-255.
4. Malek, A., Sager, R., and Schneider, H. (1994). Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy. Am. J. Reprod. Immunol. 32, 8-14.
5. Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., and Schreiber, S. (2007). PRECISE 1 Study Investigators. (2007). Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 228-238.
6. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., and Sandborn, W. J. (2007). PRECISE 2 Study Investigators. (2007). Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239-250.
7. Sheehan, K. C., Ruddle, N. H., and Schreiber, R. D. (1989). Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 142, 3884-3893.
8. Smolen, J., Landewé, R. B., Mease, P., Brzezicki, J., Mason, D., Luijtens, K., van Vollenhoven, R. F., Kavanaugh, A., Schiff, M., Burmester, G. R., et al. (2009). Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797-804.
9. Story, C. M., Mikulska, J. E., and Simister, N. E. (1994). A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 180, 2377-2381.
10. Suitters, A. J., Foulkes, R., Opal, S. M., Palardy, J. E., Emtage, J. S., Rolfe, M., Stephens, S., Morgan, A., Holt, A. R., Chaplin, L. C., et al. (1994). Differential effect of isotype on efficacy of anti-tumor necrosis factor a chimeric antibodies in experimental septic shock. J. Exp. Med. 179, 849-856.
11. Treacy, G. (2000). Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFa monoclonal antibody. Hum. Exp. Toxicol. 19, 226-228.
12. Wolf, D., and Mahadevan, U. (2010). Certolizumab use in pregnancy: low levels detected in cord blood. Arthritis Rheum. 62(Suppl. 10), S299.